-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $63

Benzinga·12/30/2025 12:46:46
Listen to the news
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $114 to $63.